๐ Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19.
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging coronavirus that has resulted in nearly 1,000,000 laboratory-confirmed cases including over 50,000 deaths. Although SARS-CoV-2 and SARS-CoV share a number of common clinical manifestations, SARS-CoV-2 appears to be highly efficient in person-to-person transmission and frequently cause asymptomatic infections. However, the underlying mechanism that confers these viral characteristics on high transmissibility and asymptomatic infection remain incompletely understood. METHODS: We comprehensively investigated the replication, cell tropism, and immune activation profile of SARS-CoV-2 infection in human lung tissues with SARS-CoV included as a comparison. RESULTS: SARS-CoV-2 infected and replicated in human lung tissues more efficiently than that of SARS-CoV. Within the 48-hour interval, SARS-CoV-2 generated 3.20 folds more infectious virus particles than that of SARS-CoV from the infected lung tissues (P<0.024). SARS-CoV-2 and SARS-CoV were similar in cell tropism, with both targeting types I and II pneumocytes, and alveolar macrophages. Importantly, despite the more efficient virus replication, SARS-CoV-2 did not significantly induce types I, II, or III interferons in the infected human lung tissues. In addition, while SARS-CoV infection upregulated the expression of 11 out of 13 (84.62%) representative pro-inflammatory cytokines/chemokines, SARS-CoV-2 infection only upregulated 5 of these 13 (38.46%) key inflammatory mediators despite replicating more efficiently. CONCLUSIONS: Our study provided the first quantitative data on the comparative replication capacity and immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung tissues. Our results provided important insights on the pathogenesis, high transmissibility, and asymptomatic infection of SARS-CoV-2.
keywords
๐ ex vivo (18)
๐ COVID-19 (1240)
๐ SARS-CoV-2 (551)
๐ coronavirus (5664)
๐ interferon (270)
๐ syndrome coronavirus (1074)
๐ infectious virus (88)
๐ virus replication (219)
๐ respiratory syndrome (2004)
๐ acute respiratory (1734)
author
๐ค Chu, Hin
๐ค Chan, Jasper Fuk-Woo
๐ค Wang, Yixin
๐ค Yuen, Terrence Tsz-Tai
๐ค Chai, Yue
๐ค Hou, Yuxin
๐ค Shuai, Huiping
๐ค Yang, Dong
๐ค Hu, Binjie
๐ค Huang, Xiner
๐ค Zhang, Xi
๐ค Cai, Jian-Piao
๐ค Zhou, Jie
๐ค Yuan, Shuofeng
๐ค Kok, Kin-Hang
๐ค To, Kelvin Kai-Wang
๐ค Chan, Ivy Hau-Yee
๐ค Zhang, Anna Jinxia
๐ค Sit, Ko-Yung
๐ค Au, Wing-Kuk
๐ค Yuen, Kwok-Yung
year
โฐ 2020
journal
๐ Clin Infect Dis
issn
๐
volume
number
page
citedbycount
0
download
๐ [BibTeX]